vedotin could be a viable treatment option for refractory CD30-positive ENKL without causing significant toxicity, even in heavily pretreated patients. However, since this case report is the first to show CR in CD30-positive ENKL with brentuximab vedotin, further studies will be required to confirm these results and establish a dosing schedule. This report implies that brentuximab vedotin could be effective in treating CD30-positive non-Hodgkin lymphoma other than ALCL and peripheral T-cell lymphoma.

**Primary bone lymphoma with multifocal osteolytic lesions: a rare case report with review of literature**

TO THE EDITOR: Primary non-Hodgkin lymphoma (NHL) of bone is a rare disorder [1]. Primary bone lymphoma involving multiple sites is even rarer and in the majority of cases, the diagnosis is diffuse large B-cell lymphoma (DLBCL). Here we report the case of a young patient with unexplained diffuse bone pain that was diagnosed as primary bone lymphoma (B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma) with multifocal osteolytic lesions.

CASE

A 22-year-old male was admitted to the orthopedic ward complaining of pain in the right side of his groin. He had experienced difficulty in walking for 3 months prior followed by diffuse bone pain in his whole body and weight loss for 2 months. He had 6 brothers and 1 sister; one of his brothers had been treated for spinal tuberculosis 9 years earlier. He was managed with analgesics and proton pump inhibitors. A skeletal survey (Fig. 1) revealed osteolytic lesions in multiple long and flat bones. Bone scintigraphy with technetium-99 showed high accumulation in the skull, vertebrae, ribs, pelvis, both humeri, and the bilateral femurs (Fig. 2A). A whole-body positron emission tomography-computed tomography (PET-CT) scan (Fig. 2B, C) revealed multiple metabolically active lytic lesions all over the skeletal system. No other metabolically active lesions were observed. Serum carcinoembryonic antigen, alpha-fetoprotein, and prostate-specific antigen levels were normal; the patient’s thyroid profile was also normal. The patient was then referred to the hematologic department.

There was no history of pallor, bleeding, arthralgia or arthritis, nor any history of blood transfusion. On examination, there was mild pallor, but no icterus, pedal edema, or palpable lymph nodes. The liver and spleen were not palpable, but bony tenderness was present. The patient was afebrile with extranodal NK/T-cell lymphoma, nasal type. Int J Clin Exp Pathol 2012;5:939-47.

1. Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008;99:1016-20.

2. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-6.

3. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30:2190-6.

4. Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 2014;123:3095-100.

5. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005;19:2186-94.

6. Falini B, Pileri S, Pizzato G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995;85:1-14.

7. Hong J, Park S, Baek HL, et al. Tumor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK/T-cell lymphoma, nasal type. Int J Clin Exp Pathol 2012;5:939-47.

8. Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood 2013;121:4997-5005.

9. Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res 2011;17:6428-36.

**REFERENCES**

1. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-6.

2. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30:2190-6.

3. Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 2014;123:3095-100.

4. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005;19:2186-94.

5. Falini B, Pileri S, Pizzato G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995;85:1-14.

6. Hong J, Park S, Baek HL, et al. Tumor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK/T-cell lymphoma, nasal type. Int J Clin Exp Pathol 2012;5:939-47.

7. Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood 2013;121:4997-5005.

8. Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res 2011;17:6428-36.
bilirubin, aspartate transaminase, alanine transaminase, and fasting plasma glucose levels. The following results were also obtained: serum total protein 4.9 g/dL, albumin 2.2 g/dL, globulin 2.7 g/dL, urea 86 mg/dL, creatinine 2.9 mg/dL, uric acid 9.9 mg/dL, sodium 128 mEq/L, potassium 2.7 mEq/L, and corrected calcium 14.20 mg/dL. The glomerular filtration rate was 23.17 mL/min, and the antinuclear antibody test result was negative. Serum and urine protein electrophoresis with immunofixation did not reveal any monoclonal paraproteins or light chains. The serum free light chain ratio was 2.54 (renal failure range, 0.37–3.17) and the β2-microglobulin level was 4,900 µg/L. Bone marrow aspiration and a trephine biopsy (Fig. 3) revealed a hypercellular marrow with diffuse infiltration by medium-to-large cells with scanty cytoplasm, vesicular nuclei with irregular nuclear membranes, and occasional cells with prominent nucleoli. A diagnosis of high-grade non-Hodgkin lymphoma (NHL) was made. The conventional cytogenetic study test results were normal, with a 46, XY karyotype. Immunohistochemistry showed that the tumor cells expressed CD20, CD10, and c-MYC, and were negative for CD3, TdT, BCL-2, and CD34. The MIB-1 labeling index was 90%. Thus, a diagnosis of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large

DISCUSSION
Coley et al. [2] described the criteria for the diagnosis of primary bone lymphoma (subsequently known as Coley’s criteria) as early as 1950. The criteria includes: (i) a primary focus in a single bone, (ii) unequivocal histologic proof from the bone lesion, and (iii) no evidence of distant soft tissue or distant lymph node involvement.

Primary lymphoma of bone is a rare entity and is generally a type of NHL; it represents <1% of all NHLs and 5% of all extranodal NHLs [1]. NHL primarily arising in bone
is unusual; its peak incidence is in the fifth decade of life. About half of primary NHLs of bone occur in the long bones [3]. It commonly presents with localized bone pain and occasionally a palpable mass [3]. Economopoulos et al. [4] from Greece studied 37 cases of primary lymphoma involving multiple extranodal sites at presentation and found only 1 case of primary bone involvement of DLBCL at multiple sites. In another study from British Columbia of 131 patients with primary bone lymphoma, the most common diagnosis was DLBCL (N=103), followed by follicular lymphoma (N=7), anaplastic large-cell lymphoma of T-cell phenotype (N=4), marginal zone lymphoma (N=4), peripheral T-cell lymphoma (N=2) and lymphoblastic lymphoma (N=2). Among others included (N=9) were 2 cases of Burkitt or Burkitt-like lymphoma and 1 unclassifiable case [5]. In a recent study from Bangalore, India, Singh et al. [6] reported 2 cases of primary bone lymphoma, both of which were diagnosed as DLBCL. Sato et al. [7] reported a case of primary bone lymphoma in a 6-year-old girl presenting with multifocal osteolytic lesions without any systemic symptoms or identifiable non-osseous primary tumors. In a recent study, it was concluded that assessment of bone marrow involvement with fluorine-18-2-deoxy-2-fluoro-D-glucose PET/CT provided a better diagnostic performance in newly diagnosed DLBCL than a bone marrow biopsy [8].

Tanaka et al. [9] reported the case of a 12-year-old boy complaining of fever and migratory arthralgia. A magnetic resonance imaging scan of his whole body showed multiple abnormal signals in his bones. Peripheral blood and bone marrow examinations did not show any abnormalities. A bone and bone marrow biopsy confirmed the diagnosis of BL on further examination. Ahn et al. [10] reported the case of a 2-year-old male Korean child admitted for left hip pain. The patient was diagnosed with intermediate DLBCL/BL based on morphological features intermediate between BL and DLBCL, expression of CD10, BCL6, BCL2, the Ki67 labeling index, and a complex karyotype with 8q34/MYC.

B-cell lymphomas with features intermediate between DLBCL and BL are aggressive lymphomas that have the morphological and genetic features of both DLBCL and BL, but biological and clinical reasons are not included in these categories [11]. Morphologic features are useful in the differential diagnosis of intermediate DLBCL/BL. There are vari-

---

**Fig. 3.** (A) Bone marrow aspiration showing few atypical mononuclear cells (arrow) with scant cytoplasm and vacuolations and occasional cells with prominent nucleoli (Leishman stain). (B-D) Trephine biopsy revealing a hypercellular marrow with diffuse infiltration by medium-to-large cells with scanty cytoplasm, vesicular nuclei with irregular nuclear membrane and occasional cells showing prominent nucleoli.
ous cellular forms; those resembling BL cells are smaller than typical DLBCL cells and those resembling DLBCL cells are larger than typical BL cells. Immunophenotypically, the cells are akin to BL with positivity for CD19, CD20, CD22, CD79a, CD10 and BCL6. BCL2 expression may be absent, weak, or strong. The Ki67 labeling index shows varying positivity [12]. Perry et al. [13] studied 39 cases of B-cell lymphoma, unclassifiable (B-UCL), presented at a median age of 69 years. The majority (62%) of patients presented with advanced-stage disease and 54% of patients had high (3-5) International Prognostic Index scores. Genetic heterogeneity was observed; 11 patients had ‘double-hit’ lymphomas with rearrangements of both MYC and BCL2 or BCL6. None of the immunohistochemical or genetic features were predictive of survival and the cases were very aggressive and resistant to chemotherapy. The 2008 World Health Organization classification includes provisional borderline categories for cases that are not clearly DLBCL or BL. This new category is called B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL (intermediate DLBCL/BL) [11]. The justification for this new category is the recognition that these tumors are frequently refractory to chemotherapy and the patients have a poor survival rate [14]. Sirelkhatim et al. [15] studied cases with unexplained bone pain and concluded that lymphoma/leukemia should be kept in mind when investigating a case of unexplained bone pain or an unexplained bone lesion, although it is a rare entity.

Our case presented with unexplained diffuse bone pain and, on evaluation, the patient was diagnosed with primary bone lymphoma (B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL). The features included: a young age at presentation, serum hypercalcemia, multifocal osteolytic lesions present all over the body, and a rare type of histologic diagnosis. The patient achieved complete remission with R-CHOP chemotherapy. Ramadan et al. [5] treated the cases with CHOP (and R-CHOP in the rituximab era), radiotherapy or a combination of both.

NHL presenting as a primary bone tumor with multifocal disease is extremely rare. Primary bone lymphoma should be considered in the differential diagnosis of bony lesions in young patients. A very high index of suspicion, judicious use of the investigative armamentarium, and awareness of provisional borderline categories like B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL will help clinicians to achieve timely diagnosis and management.

Prakas Kumar Mandal, Shuvraeneel Baul, Tuphan Kanti Dolai

Department of Hematology, NRS Medical College, Kolkata, India

Correspondence to: Prakas Kumar Mandal

Department of Hematology, NRS Medical College, 8C/1/N, Roy Para Road, Kolkata 700050, India

E-mail: prakas70@gmail.com

Received on Jan. 14, 2015; Revised on Jan. 28, 2015; Accepted on Nov. 12, 2015

http://dx.doi.org/10.5045/br.2015.50.4.256

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

REFERENCES

1. de Leval L, Braaten KM, Ancukiewicz M, et al. Diffuse large B-cell lymphoma of bone: an analysis of differentiation-associated antigens with clinical correlation. Am J Surg Pathol 2003;27:1269-77.

2. Coley BL, Higinbotham NL, Groesbeck HP. Primary reticulum-cell sarcoma of bone; summary of 37 cases. Radiology 1950;55:641-58.

3. Gill P, Wenger DE, Inwards DJ. Primary lymphomas of bone. Clin Lymphoma Myeloma 2005;6:140-2.

4. Economopoulos T, Pagapeorgiou S, Rontogianni D, et al. Multifocal extranodal non-hodgkin lymphoma: a clinicopathologic study of 37 cases in Greece, a Hellenic Cooperative Oncology Group study. Oncologist 2005;10:734-8.

5. Ramadan KM, Shenkier T, Sehn LH, Gascoyne RD, Connors JM. A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successfully treated cohorts from the British Columbia Cancer Agency. Ann Oncol 2007;18:129-35.

6. Singh T, Satheesh CT, Lakshmaiah KC, et al. Primary bone lymphoma: a report of two cases and review of the literature. J Cancer Res Ther 2010;6:296-8.

7. Sato TS, Ferguson PJ, Khanna G. Primary multifocal osseous lymphoma in a child. Pediatr Radiol 2008;38:1338-41.

8. Berthet L, Cochet A, Kanoun S, et al. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med 2013;54:1244-50.

9. Tanaka C, Nozawa K, Sano A, et al. A case of Burkitt lymphoma with multifocal bone invasion. Rinsho Byori 2013;61:231-6.

10. Ahn JY, Seo YH, Park PW, et al. A case of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma in a Korean child. Ann Lab Med 2012;32:162-6.

11. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press, 2008:65-6.

12. Carbone A, Gloghini A, Aiello A, Testi A, Cabras A. B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology. Hum Pathol 2010;41:621-31.

13. Perry AM, Crockett D, Dave BJ, et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma: study of 39 cases. Br J Haematol 2013;162:40-9.

14. Jack AS, Barrans SL, Qian W, Stenning SP, Mead GM. Bone marrow involvement and outcome in Burkitt lymphoma and diffuse large B-cell lymphoma. Blood 2009;114:486-7.
TO THE EDITOR: Multicentric Castleman disease (MCD) is usually a progressive systemic disease that has a worse prognosis than the unicentric form. The treatment of MCD is based on systemic therapies, such as chemotherapy and monoclonal antibodies. Imaging procedures play an important role in defining the response to treatment. However, no radiologic linchpins exist, due to the lack of evidence.

Castleman disease (CD) is a rare lymphoproliferative disorder first described by Benjamin Castleman, a pathologist at the Massachusetts General Hospital. CD may be unicentric or multicentric. Unicentric CD (UCD), the most common form, is localized and may often be successfully treated with local therapies. MCD is a systemic disease, occurs most commonly in the setting of human immunodeficiency virus (HIV) infection, is usually progressive, and has a worse prognosis. The management of MCD may be carried out by systemic therapies. In the past, the diagnostic imaging of CD has largely been supported by conventional structural imaging techniques, such as computed tomography (CT) and magnetic resonance imaging (MRI), as well as by traditional nuclear medicine examinations, such as $^{67}$Ga scan. In the past two decades, $^{18}$F-fluorodeoxyglucose ($^{18}$F-FDG) positron emission tomography (PET/CT) has become an established imaging tool in oncology. In addition, PET/CT has been generating increasing interest in the areas of infectious diseases [1] and fever of unknown origin [2], as well as with lymphoproliferative disorders such as CD [3, 4] particularly in individuals with HIV infection [5]. Here, we present the case of a patient affected by MCD who underwent PET/CT for staging and restaging of the disease. In the diagnostic setting, PET/CT contributed to the identification of the most appropriate node to select for biopsy, whereas it provided objective information regarding the early response to therapy during the restaging.

CASE

In June 2012, a 50-year-old man presented to our hospital with a pruritic papular skin rash of the lower limbs, xerostomia associated with a 6 kg weight loss, asthenia, weakness of the lower limbs, and dyskinesia. The preliminary laboratory tests showed hypergammaglobulinemia, elevated liver enzymes, and values suggestive of an inflammatory state. Bilateral laterocervical and inguinal lymph nodes were observed on the medical evaluation. Additional tests revealed that the hypergammaglobulinemia was polyclonal with a prevalence of the immunoglobulin G (IgG) cluster (50 g/L) and increases in the light kappa and lambda chains. Moreover, C3 and C4 complement proteins were decreased, whereas beta-2 microglobulin was increased. The serology tests for cryoglobulin, antinuclear antibody (ANA), antimitochondrial antibody (AMA), anti-extractable nuclear antigen (ENA), antineutrophil cytoplasmic antibody (ANCA), anti-deoxyribonucleic acid (DNA), lupus anticoagulant (LAC), HIV, Hepatitis B virus (HBV), Salmonella, Brucella, Leishmania, Parvovirus, Strongyloides Stercoralis, Bartonella, Epstein-Barr virus (EBV), and cytomegalovirus (CMV) were negative. The CT scan showed slightly enlarged lymph nodes in the mediastinum, retroperitoneum, and iliac regions. Electromyography (EMG) reported mild sensorimotor neuropathy.

PET/CT scanning (Siemens Biograph PET/CT scanner) was performed from the base of the skull to the upper thorax and abdomen. The images showed multiple areas of increased uptake corresponding to the enlarged nodes.